How much does Bimekizumab cost?

Bimekizumab is an interleukin inhibitor used to treat plaque psoriasis in adults. Bimezumab reduces inflammation and improves symptoms of plaque psoriasis by inhibiting two proteins (IL-17A and IL-17F) that are involved in the inflammatory process of psoriasis. Bimezumab can be self-injected by patients as a subcutaneous injection (under the skin), initially every 4 weeks and then every 8 weeks.

Bimegizumab became a U.S. Food and Drug Administration (FDA) approved drug on October 18, 2023; the approval was based on the positive results of three phase 3 randomized clinical trials (BE READY, BE VIVID and BE SURE). In these clinical trials, bimeclizumab was consistently effective in improving plaque psoriasis and maintaining durable levels of skin clearance. Bimezumab is therefore indicated for the treatment of adults with moderate to severe plaque psoriasis who may benefit from systemic or phototherapy. Studies showthe positive effects of this drug last up to a year of use. Side effects are consistent with other similar medications, with the most important being nose and throat infections and candidiasis (a yeast[fungal] infection) in the mouth or throat.

The generic drug Bimeizumab has not yet been launched in the country, so it cannot be included in medical insurance. The European version of bimezumab original drug sold overseas, specifications160mg*2 per box may cost more than 40,000 yuan (the price may fluctuate due to the exchange rate). The price is still relatively high. There is currently no generic version of bimezumab produced and launched. For the specific price and drug information of this drug, please consult a medical consultant.